With Lipitor -- at one point the best selling drug in the world -- now off patent, will Pfizer's dividend continue to grow?
The numbers might look conducive for a dividend hike, but make sure you do your homework before investing in Bristol-Myers Squibb.
Unlike its growth-oriented biotech peers, Amgen showed that it's no longer a youngster by initiating a dividend in 2011.
Eli Lilly faces one of the more significant patent cliffs in the pharmaceutical industry. But will losing patent protection mean the company's dividend is at risk?
Intuitive Surgical shares just hit a new 52-week low, but this analyst thinks its a buying opportunity.
The pharmaceutical industry's leader in diabetes doesn't have the highest dividend yield, but might have the greatest future prospects relative to its peers.
AstraZeneca has a big dividend, but faces an even bigger challenge with the patent expiration dates for Nexium and Crestor looming.
Generic competition for this pharmaceutical company's top drug is weighing on revenue growth in the near-term; but what does this mean for the dividend?
As investors look far and wide for dividend yield, can they continue to rely on the 800 pound gorilla of health care, Johnson & Johnson?
Generic drug-makers typically prosper from off-patent drugs, but its a mixed bag for Teva, who relies on a blockbuster multiple sclerosis drug that will come off patent in the next few years.
PDL BioPharma is one of the top dividend stocks in the health care industry. But is there a reason this stock trades at such a high yield?
Does this controversial pharmaceutical dividend stock have more room to run?
A new Affordable Care Act rule aims to help mothers embrace breast feeding instead of using baby formula. Will this hurt infant nutrition companies?
There's a strong argument to be made that an FDA rule is the primary problem causing thousands of metal-on-metal artificial hip recalls over the past few years.
Merck shares gain as investors reassess the odds that sales of a controversial cholesterol drug, Vytorin, will grow even larger.
Expanding Medicaid to a huge number of new Americans seems highly lucrative for managed care companies, but there may be some unpredictable headwinds.
Pharmaceutical companies take advantage of tax havens to boost profits for investors. But there is a disadvantage investors might not be aware of.
An ironic new move for Wal-Mart.
Health care reform was created to expand coverage to all Americans. But what if states don't cooperate?
Are pharmaceuticals a steal at these prices?